Surgery Partners, Inc. (SGRY)
NEUTRALFundamental
54
Kurs
$13.99
Marktkapitalisierung
$1.90B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$3.37B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-89M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$196M
Gesamtes Eigenkapital
$1.71B
Gesamtverbindlichkeiten
$4.99B
Current Ratio
1.95
Zinsdeckungsgrad
-
Schulden/EBITDA
7.18
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$17.17
Aktueller Kurs
$13.99
Sicherheitsmarge
+18.5%
Innerer-Wert-Spanne
$14.82 - $19.53
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-4.5%
P/B-Verhältnis
1.09
P/FCF
9.74
Bruttomarge
-
ROIC
4.1%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
4.1%
WACC
4.9%
ROIC − WACC
-0.9 pp
ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.
Fundamentalanalyse-Kriterien
Bestanden (12)
- P/FCF 9.74
- P/B Ratio 1.09
- Debt/Equity ratio
- Operating Margin 11.4%
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 12.2%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 14.8%
- Share Dilution 1.0%
- Net Margin Trend -2.6% vs -5.6%
- Piotroski F-Score 5/9
Nicht bestanden (9)
- EPS shows upward trend
- Price CAGR -0.87%
- ROIC 4.1%
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- ROE -5.3%
Nicht verfügbar (6)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienanzahl ist stabil
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. J. Eric Evans | CEO & Director | 48 |
| Mr. David T. Doherty CPA | Executive VP & CFO | 53 |
| Ms. Jennifer B. Baldock J.D. | Executive VP and Chief Administrative & Development Officer | 54 |
| Ms. Marissa A. Brittenham | Executive VP & Chief Strategy Officer | 40 |
| Mr. W. Trent Webb | Division President South | 45 |
| Mr. Justin R. Oppenheimer | Executive VP & COO | 40 |
| Mr. Jon Fredrickson | Senior VP & Chief Information Officer | - |
| Ms. Roxanne Womack | Senior VP & Chief Compliance Officer | - |
| Mr. Spencer Clark | General Counsel & Senior VP | - |
| Ms. Danielle Burkhalter | Executive VP & Chief Human Resources Officer | 40 |
Prüfungsrisiko
9
Vorstandsrisiko
6
Vergütungsrisiko
4
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for SGRY, sourced from Markets Gazette.
- 3/3/2026NEGATIVESurgery Partners Stock Hits 52-Week Low - Here's Why
Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.
- 2/23/2026NEGATIVESurgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million
Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.
via Markets Gazette